key: cord-0775302-8oqxz5o1
authors: Parry, Helen; Bruton, Rachel; Roberts, Thomas; McIlroy, Graham; Damery, Sarah; Sylla, Panagiota; Dowell, Alexander C.; Tut, Gokhan; Lancaster, Tara; Bone, David; Willett, Brian; Logan, Nicola; Scott, Sam; Hulme, Sam; Jadir, Azar; Amin, Umayr; Nicol, Sam; Stephens, Christine; Faustini, Sian; Al-Taei, Saly; Richter, Alex; Blakeway, Daniel; Verma, Kriti; Margielewska-Davies, Sandra; Pearce, Hayden; Pratt, Guy; Zuo, Jianmin; Paneesha, Shankara; Moss, Paul
title: COVID-19 vaccines elicit strong cellular immunity and robust clinical protection in CLL
date: 2022-05-06
journal: Cancer Cell
DOI: 10.1016/j.ccell.2022.05.001
sha: 3fe223803769c1f7d36a4e52eebbf25ccf3b4eca
doc_id: 775302
cord_uid: 8oqxz5o1

nan

B cell chronic lymphocytic leukaemia (CLL) is the most common subtype of adult leukaemia and is associated with profound secondary immunodeficiency. SARS-CoV-2 infection has been a significant cause of morbidity and mortality (Mato et al., 2020; Pagano et al., 2021) and immunological responses against SARS-CoV-2 vaccines are impaired (Fendler et al., 2021) in patients with CLL. In particular, reduced rates of seroconversion and antibody titre have been reported (Parry et al., 2021; Greenberger et al., 2021; Herishanu et al., 2022) and associate with reduced serum immunoglobulin level or use of medication such as Bruton tyrosine kinase inhibitors or anti-CD20 antibodies (Parry et al., 2021; Herishanu et al., 2022) .

However, questions regarding optimal immune protection remain unresolved including the potential for additional vaccine doses to increase seroconversion rate, potential humoral and cellular immune protection against Omicron, and the impact of vaccine delivery on breakthrough infection rate and clinical outcome.

We determined antibody and cellular immune responses after 3 rd and 4 th vaccine dose in participants of the CLL-VR study together with age-matched healthy donor controls (n=93).

Blood samples were taken from 404 patients at a median time of 20 days following 3 rd dose, of which 161 (40%) had received the BNT162b2 vaccine (Pfizer/BioNTech) as primary series and 243 (60%) had received the ChAdOx1 vaccine (Oxford/AstraZeneca). Almost all patients (393/404) received an mRNA vaccine for 3 rd dose (375: BNT162b2; 18: mRNA-1273). Samples were also collected from 186 patients following the 4 th vaccine dose (Table   S1 ). Patients with clinical or serological evidence of prior natural SARS-CoV-2 infection were excluded from analysis.

Spike-specific antibody responses have previously been reported to develop in 66% (322/486) of patients within the CLL-VR study following the first 2 vaccine doses compared to 100% of controls (Parry et al., 2021) . This response rate improved to 80% following the 3 rd vaccine dose (298/374) (p<0.0001) ( Figure S1A) However, the seroconversion rate was not increased further after a 4 th vaccine (77%; 132/171) indicating that the proportion of patients who develop a spike-specific antibody response following COVID-19 vaccination plateaus after the 3 rd vaccine ( Figure S1A ). Three seronegative patients became available for study following a breakthrough infection and J o u r n a l P r e -p r o o f natural infection also failed to generate spike-specific antibodies, indicating that seronegative patient subgroup are broadly refractory to seroconversion. Regardless of vaccine dose number, a low serum IgM, current BTKi therapy or imminent planned treatment were independent predictors of poor response with an 81% (p=0.003), 90% (p=0.021) and 96% (p=0.027) reduction in probability of response respectively after the 4 th dose.

In those patients with a positive antibody response following vaccination, titers increased by 4.5-fold after the 3 rd vaccine dose (Geometric mean [GM] Figure S1C ).

Response was found to be markedly higher after 3 rd dose in patients who had a heterologous We next assessed the quality of humoral and cellular vaccine-induced immunity against the Omicron variant that has become globally dominant since its original description in November 2021. Neutralising antibody titers after 3rd vaccine dose were markedly reduced against Omicron compared to ancestral variant but were equivalent in patients and controls Figure   S1D ). In contrast, ELISpot analysis of peptide specific pools for ancestral and Omicron showed no difference in the magnitude of the cellular responses amongst vaccinated CLL patients, with a median 246 SFC/10 6 PBMC (IQR 85-679) against ancestral peptides compared to 238 SFC/10 6 against Omicron peptides (IQR 71-725; p=0.33) ( Figure S1E ). As such, vaccine-induced cellular responses in patients with CLL may provide strong crossprotection against the Omicron variant.

Clinical data on breakthrough infection were collected from the whole cohort on 21 February, 2022. At that point, 491 participants remained in study (7 participants had withdrawn and 2 participants had non-COVID-related mortality). Data were obtained on 486 participants (99%) and the remaining 5 were confirmed to be alive. 79/486 (16%) reported a confirmed COVID-19 infection at least once since vaccination. A further 8 donors were found to be nucleocapsid-specific antibody positive without a history of infection and together 18% (87/486) of participants suffered SARS-CoV-2 breakthrough infection.

We next obtained information on breakthrough infection to assess if correlates of protection might be observed within the CLL-VR cohort. 66 of 486 patients (14%) reported a COVID-19 infection during the 14 months since the first vaccine dose was administered, of which 3 also had a reinfection. 5 infections (7.6%) occurred between January-June 2021 when the Alpha variant was dominant, 22 (33%) between July-December 2021 during the Delta wave and 39 cases (59%) in the last 3 months during Omicron transmission. The proportion of patients requiring hospitalisation during these three phases was 20% (1/5), 32% (7/22) and 7.7% (3/39), respectively ( Figure S1F ).

Somewhat unexpectedly, patients who were seropositive after the second dose showed a 79% increase in infection rate (n=471; HR 1.79 [95% CI 1.0-3.1]; p=0.046) during median follow up time of 46 (IQR 43-54) weeks. Younger age (p=0.001) and low total serum IgM (p=0.03) were independent predictors for breakthrough infection by multivariate analysis.

These findings reveal the utility and limitations of current COVID-19 vaccines in patients with CLL. Although 3 vaccine doses increase the rate of seroconversion to 80%, it represents a plateau that is not overcome by further vaccine doses or natural infection. As a result, 20% of patients continue to lack any detectable anti-spike response, reflecting the inherent immunodeficiency of CLL and the immunosuppressive impact of CLL-directed therapy.

Indeed, hypogammaglobulinaemia and BTKi therapy were also associated with failure of seroconversion in patients following breakthrough infection. This patient group appear resistant to improvement in humoural immunity and require alternative approaches for immune protection, such as prophylactic monoclonal antibody treatment.

However, there were also encouraging findings. Antibody titres after 3 vaccine doses in those patients who did develop an antibody response were comparable with those seen in healthy donors after primary series vaccination. Furthermore, cellular immune responses J o u r n a l P r e -p r o o f were also comparable. Homologous and heterologous vaccination protocols elicited comparable humoral responses although cellular immunity was stronger following ChAdOx1 primary series. A similar finding has been reported in healthy donors and patients with other hematologic malignancies, and suggests that adenoviral-based vaccines may be particularly effective in generating cellular immunity in patients with immune suppression (Collier et al., 2021; Lim et al., 2022) . Furthermore, we found neutralization of Omicron was low, although values were broadly equivalent in both CLL participants and controls following a third vaccine dose, whereas cellular responses against Omicron were equivalent to those seen against the ancestral strain amongst vaccinated CLL patients.

The most important consideration in SARS-CoV-2 vaccination is clinical efficacy. Vaccine breakthrough infection occurred in 14% of patients but encouragingly there were no COVID-19-related deaths in this cohort that were recruited at the time of the vaccination roll out.

The observed increased risk of infection in seropositive patients is thought likely to reflect differences in social behaviour and population mixing as this group was younger than the group that remained seronegative. However, this observation emphasizes that definition of an immune correlate of protection will be challenging in patients with immune suppression and indicates a need for caution in predicting individual infection risk on the basis of antibody status in the clinic. Hospitalisation rates were high, at 32% for the pre-Omicron variants although falling to 7.7% during the Omicron wave. Monoclonal antibody therapy became available in the community in December 2021 and may have contributed to the reduced rate of hospitalisation, although only 36% of those testing positive during the same period received therapy.

In conclusion, SARS-CoV-2 vaccines are currently providing robust clinical protection for patients with CLL but approximately 20% of patients are refractory to seroconversion and are at increased risk of infection. In contrast, cellular responses after vaccination are comparable with healthy donors and may be critical for preventing severe disease. 

Patients with a diagnosis of CLL or small lymphocytic leukaemia (SLL) were recruited to study with no additional exclusion criteria. Informed consent was obtained by remote consultation and work performed under the CIA UPH IRAS approval (REC 20\NW ) from North-West and Preston ethics committee and conducted according to the Declaration of Helsinki. The dates and type of SARS-CoV-2 vaccination were obtained with self-reported information on stage and date of CLL diagnosis, CLL treatment and infection history as previously described. Participant demographics can be found in Table S1 .

Samples were obtained 2-3 weeks following the second, third and fourth dose of vaccination.

Local participants undertook phlebotomy whilst those more distant donated a dried blood spot sample (DBS). 93 healthy donor controls were recruited from local primary care networks (median age 73; (IQR 68-74.5); 56 were female (60%) and 59 received ChAdOx1 primary course and 34 received BNT162b2) .

Using ECLIA, qualitative IgG/A/M Anti-nucleocapsid protein (NP) antibodies specific to SARS-CoV-2 were detected (COV2, Product code: 09203079190); cut-off index value ≥1.0 considered positive for anti-nucleocapsid antibodies. Using the quantitative ECLIA assay, anti-spike (S) receptor binding domain antibodies were detected (COV2 S, Product code 09289275190) with values ≥0.8 U/ml considered positive.

Dried blood spot (DBS) analysis was carried out as previously described to ascertain the sero-positive rate amongst donors (Cook et al., 2021) . IgG, IgA and IgM antibody isotypes against stabilised trimeric SARS-CoV-2 spike glycoprotein are reported with a positive result classed as a ratio of 1 or more.

Quantification of IgG, IgA and IgM was evaluated using the COBAS 6000 (Roche) at the University of Birmingham Clinical Immunology Service as previously described (Parry et al., 2021) .

J o u r n a l P r e -p r o o f

The delta construct bore the following mutations relative to the ancestral Hu-1 sequence (GenBank: MN908947): T19R, G142D, E156del, F157del, R158G, L452R, T478K, D614G, P681R, D950N. 293-ACE2 was serially diluted in triplicate from 1:50 to 1:36,450 in complete DMEM prior to incubation with approximately 1x10 6 CPS per well of HIV (SARS-CoV-2) pseudotypes, incubated for 1 hour, and plated onto 239-ACE2 target cells. Luciferase activity was quantified after 48-72 hours by the addition of Steadylite Plus chemiluminescence substrate and analysis on a Perkin Elmer EnSight multimode plate reader (Perkin Elmer

QuantiFERON Mitogen BCTs (positive control) and a QFN SARS CoV-2 Ag2 tube containing epitopes from while spike that simulate both CD4+ and CD8+ T cells. After 18hr incubation, plasma was retrieved from each tube and an ELISA for IFN-γ release performed (Catalogue number 626410 QuanitFERON ELISA, Qiagen). The concentration of

IU/ml was confirmed after deduction of the QFN-SARS-CoV-2 Nil concentration. the Omicron variant ( PepMixâ„¢ SARS-CoV-2 (Spike B.1.1.529 / Omicron)Product Code

T cell responses were determined using a Human IFNγ ELISpot PRO kit (3420-3PT Mabtech, Sweden) and plates read using the Bioreader5000

U-tests or Spearman rank correlation were performed and antibody data presented either as median or geometric means + 95% confidence intervals. Kruskal-Wallis was performed with post-hoc Dunn's analysis for comparative groups and Wilcoxon's matched-pairs signed rank test for paired responses. Logistic regression of clinical variables was tested for associations with positive antibody response after each vaccine dose. Chi-square analysis was used to compare proportions of responders and Kaplan-Meier for time to first treatment with Gehan-Breslow-Wilcoxon test reported. Analysis was performed using Graphpad prism v9.1.0 for Mac

Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism

This work was supported by National Core Studies Immunity and the UK Coronavirus Immunology Consortium (UK-CIC) funded by NIHR/UKRI. BW received support from BBSRC (BB/R004250/1 and BB/R019843/1) and MRC (MC_UU_12014/1). We thank Dr Rory Meade and the patients and staff at Harborne Medical Practice. We also thank Millie Manning, Danielle Sutherland, Tamsin Drury and Alex Bray for their help in recruitment. HP,